心肌活性检测在缺血性心肌病患者血运重建中的应用现状

doi:10.12114/j.issn.1007-9572.2024.0132

摘要/Abstract

摘要： 缺血性心肌病（ICM）是引起射血分数减低性心力衰竭的重要病因，尽管治疗手段在不断提高，但是仍具有较高的死亡率。血运重建是ICM患者重要的治疗方法，由于ICM患者多为老年人、合并多种基础疾病且冠状动脉病变重，血运重建的风险较高，目前对于ICM患者是否血运重建及血运重建的方式仍存在争议。心肌活性对ICM患者的预后具有预测价值，并为选择治疗策略提供参考，但是其对ICM患者血运重建的指导价值仍有待进一步验证。现对ICM患者目前治疗现状、心肌活性评估的常用方法以及临床应用心肌活性评估指导血运重建的现状进行综述，为临床ICM的治疗提供参考。

关键词: 缺血性心肌病, 血运重建, 心肌活性, 研究进展

Abstract:

Ischemic cardiomyopathy (ICM) is an important cause of heart failure with reduced ejection fraction. Despite the improvement of treatment methods, it still has a high mortality. Coronary revascularization is an important treatment for ICM patients, due to the fact that ICM patients are elderly, have multiple diseases and severe coronary artery lesions, the risk of revascularization is relatively high. Currently, there is still controversy over whether and how to revascularization in ICM patients. Myocardial viability has predictive value for the prognosis of ICM patients and provides reference for selecting treatment strategies, but its guiding value for revascularization in ICM patients still needs further verification. This article provides a review of the current treatment of ICM patients, commonly used methods for myocardial viability assessment, and the clinical application of myocardial viability to guide revascularization, so as to provide reference for clinical work.

Key words: Ischemic heart diseases, Revascularization, Myocardial viability, Research progress

苏利芳,汪雁博,姜云发,等. 心肌活性检测在缺血性心肌病患者血运重建中的应用现状[J]. 中国全科医学, 2025, 28(09): 1137-1142. DOI: 10.12114/j.issn.1007-9572.2024.0132.
SU Lifang,WANG Yanbo,JIANG Yunfa, et al. Myocardial Viability Testing in Patients with Ischemic Cardiomyopathy[J]. Chinese General Practice, 2025, 28(09): 1137-1142. DOI: 10.12114/j.issn.1007-9572.2024.0132.

参考文献 54

[1]	FELKER G M，SHAW L K，O'CONNOR C M. A standardized definition of ischemic cardiomyopathy for use in clinical research[J]. J Am Coll Cardiol，2002，39（2）：210-218. DOI：10.1016/s0735-1097(01)01738-7.
[2]	CABAC-POGOREVICI I，MUK B，RUSTAMOVA Y，et al. Ischaemic cardiomyopathy. Pathophysiological insights，diagnostic management and the roles of revascularisation and device treatment. Gaps and dilemmas in the era of advanced technology[J]. Eur J Heart Fail，2020，22（5）：789-799. DOI：10.1002/ejhf.1747.
[3]	SHAH B N，KHATTAR R S，SENIOR R. The hibernating myocardium：current concepts，diagnostic dilemmas，and clinical challenges in the post-STICH era[J]. Eur Heart J，2013，34（18）：1323-1336. DOI：10.1093/eurheartj/eht018.
[4]	BRAUNWALD E，KLONER R A. The stunned myocardium：prolonged，postischemic ventricular dysfunction[J]. Circulation，1982，66（6）：1146-1149. DOI：10.1161/01.cir.66.6.1146.
[5]	ALMEIDA A G，CARPENTER J P，CAMELI M，et al. Multimodality imaging of myocardial viability：an expert consensus document from the European Association of Cardiovascular Imaging （EACVI）[J]. Eur Heart J Cardiovasc Imaging，2021，22（8）：e97-125. DOI：10.1093/ehjci/jeab053.
[6]	ALLMAN K C，SHAW L J，HACHAMOVITCH R，et al. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction：a meta-analysis[J]. J Am Coll Cardiol，2002，39（7）：1151-1158. DOI：10.1016/s0735-1097(02)01726-6.
[7]	NEUMANN F J，SOUSA-UVA M，AHLSSON A，et al. 2018 ESC/EACTS guidelines on myocardial revascularization[J]. Eur Heart J，2019，40（2）：87-165. DOI：10.1093/eurheartj/ehy394.
[8]	PONIKOWSKI P，VOORS A A，ANKER S D，et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure：the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology（ESC） Developed with the special contribution of the Heart Failure Association（HFA） of the ESC[J]. Eur Heart J，2016，37（27）：2129-2200. DOI：10.1093/eurheartj/ehw128.
[9]	KNUUTI J，WIJNS W，SARASTE A，et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes[J]. Eur Heart J，2020，41（3）：407-477. DOI：10.1093/eurheartj/ehz425.
[10]	VELAGALETI R S，VETTER J，PARKER R，et al. Change in left ventricular ejection fraction with coronary artery revascularization and subsequent risk for adverse cardiovascular outcomes[J]. Circ Cardiovasc Interv，2022，15（4）：e011284. DOI：10.1161/CIRCINTERVENTIONS.121.011284.
[11]	ADACHI Y，SAKAKURA K，WADA H，et al. Determinants of left ventricular systolic function improvement following coronary artery revascularization in heart failure patients with reduced ejection fraction（HFrEF）[J]. Int Heart J，2016，57（5）：565-572. DOI：10.1536/ihj.16-087.
[12]	LOPES R D，ALEXANDER K P，STEVENS S R，et al. Initial invasive versus conservative management of stable ischemic heart disease in patients with a history of heart failure or left ventricular dysfunction：insights from the ISCHEMIA trial[J]. Circulation，2020，142（18）：1725-1735. DOI：10.1161/CIRCULATIONAHA.120.050304.
[13]	PERERA D，CLAYTON T，O'KANE P D，et al. Percutaneous revascularization for ischemic left ventricular dysfunction[J]. N Engl J Med，2022，387（15）：1351-1360. DOI：10.1056/NEJMoa2206606.
[14]	VELAZQUEZ E J，LEE K L，DEJA M A，et al. Coronary-artery bypass surgery in patients with left ventricular dysfunction[J]. N Engl J Med，2011，364（17）：1607-1616. DOI：10.1056/NEJMoa1100356.
[15]	VELAZQUEZ E J，LEE K L，JONES R H，et al. Coronary-artery bypass surgery in patients with ischemic cardiomyopathy[J]. N Engl J Med，2016，374（16）：1511-1520. DOI：10.1056/NEJMoa1602001.
[16]	BANGALORE S，GUO Y，SAMADASHVILI Z，et al. Revascularization in patients with multivessel coronary artery disease and severe left ventricular systolic dysfunction：everolimus-eluting stents versus coronary artery bypass graft surgery[J]. Circulation，2016，133（22）：2132-2140. DOI：10.1161/CIRCULATIONAHA.115.021168.
[17]	SUN L Y，GAUDINO M，CHEN R J，et al. Long-term outcomes in patients with severely reduced left ventricular ejection fraction undergoing percutaneous coronary intervention vs coronary artery bypass grafting[J]. JAMA Cardiol，2020，5（6）：631-641. DOI：10.1001/jamacardio.2020.0239.
[18]	PATEL M R，CALHOON J H，DEHMER G J，et al. ACC/AATS/AHA/ASE/ASNC/SCAI/SCCT/STS 2017 appropriate use criteria for coronary revascularization in patients with stable ischemic heart disease：a report of the American College of Cardiology appropriate use criteria task force，American association for Thoracic Surgery，American Heart Association，American Society of Echocardiography，American Society of Nuclear Cardiology，Society for Cardiovascular angiography and interventions，society of cardiovascular computed tomography，and society of thoracic surgeons[J]. J Am Coll Cardiol，2017，69（17）：2212-2241. DOI：10.1016/j.jacc.2017.02.001.
[19]	PETRIE M C，JHUND P S，SHE L L，et al. Ten-year outcomes after coronary artery bypass grafting according to age in patients with heart failure and left ventricular systolic dysfunction：an analysis of the extended follow-up of the STICH trial （surgical treatment for ischemic heart failure）[J]. Circulation，2016，134（18）：1314-1324. DOI：10.1161/CIRCULATIONAHA.116.024800.
[20]	PANZA J A，VELAZQUEZ E J，SHE L L，et al. Extent of coronary and myocardial disease and benefit from surgical revascularization in ischemic LV dysfunction[J]. J Am Coll Cardiol，2014，64（6）：553-561. DOI：10.1016/j.jacc.2014.04.064.
[21]	DEJA M A，GRAYBURN P A，SUN B，et al. Influence of mitral regurgitation repair on survival in the surgical treatment for ischemic heart failure trial[J]. Circulation，2012，125（21）：2639-2648. DOI：10.1161/CIRCULATIONAHA.111.072256.
[22]	ACERBO V，CESARO A，SCHERILLO G，et al. Understanding the role of coronary artery revascularization in patients with left ventricular dysfunction and multivessel disease[J]. Heart Fail Rev，2023，28（6）：1325-1334. DOI：10.1007/s10741-023-10335-0.
[23]	RYAN M，MORGAN H，CHIRIBIRI A，et al. Myocardial viability testing：all STICHed up，or about to be REVIVED?[J]. Eur Heart J，2022，43（2）：118-126. DOI：10.1093/eurheartj/ehab729.
[24]	中华医学会核医学分会，中华医学会心血管病学分会. 核素心肌显像临床应用指南（2018）[J]. 中华心血管病杂志，2019，47（7）：519-527. DOI：10.3760/cma.j.issn.0253-3758.2019.07.003.
[25]	DILSIZIAN V，BACHARACH S L，BEANLANDS R S，et al. ASNC imaging guidelines/SNMMI procedure standard for positron emission tomography（PET） nuclear cardiology procedures[J]. J Nucl Cardiol，2016，23（5）：1187-1226. DOI：10.1007/s12350-016-0522-3.
[26]	BAX J J，POLDERMANS D，ELHENDY A，et al. Sensitivity，specificity，and predictive accuracies of various noninvasive techniques for detecting hibernating myocardium[J]. Curr Probl Cardiol，2001，26（2）：147-186. DOI：10.1067/mcd.2001.109973.
[27]	HENZLOVA M J，DUVALL W L，EINSTEIN A J，et al. ASNC imaging guidelines for SPECT nuclear cardiology procedures：stress，protocols，and tracers[J]. J Nucl Cardiol，2016，23（3）：606-639. DOI：10.1007/s12350-015-0387-x.
[28]	SCHINKEL A F L，BAX J J，POLDERMANS D，et al. Hibernating myocardium：diagnosis and patient outcomes[J]. Curr Probl Cardiol，2007，32（7）：375-410. DOI：10.1016/j.cpcardiol.2007.04.001.
[29]	UDELSON J E，COLEMAN P S，METHERALL J，et al. Predicting recovery of severe regional ventricular dysfunction. Comparison of resting scintigraphy with 201Tl and 99mTc-sestamibi[J]. Circulation，1994，89（6）：2552-2561. DOI：10.1161/01.cir.89.6.2552.
[30]	JASMIN N H，THIN M Z，JOHNSON R D，et al. Myocardial viability imaging using manganese-enhanced mri in the first hours after myocardial infarction[J]. Adv Sci，2021，8（11）：e2003987. DOI：10.1002/advs.202003987.
[31]	SELVANAYAGAM J B，KARDOS A，FRANCIS J M，et al. Value of delayed-enhancement cardiovascular magnetic resonance imaging in predicting myocardial viability after surgical revascularization[J]. Circulation，2004，110（12）：1535-1541. DOI：10.1161/01.CIR.0000142045.22628.74.
[32]	ADHADUK M，PAUDEL B，LIU K，et al. Comparison of cardiac magnetic resonance imaging and fluorodeoxyglucose positron emission tomography in the assessment of myocardial viability：meta-analysis and systematic review[J]. J Nucl Cardiol，2023，30（6）：2514-2524. DOI：10.1007/s12350-023-03377-2.
[33]	BAER F M，VOTH E，SCHNEIDER C A，et al. Comparison of low-dose dobutamine-gradient-echo magnetic resonance imaging and positron emission tomography with[18F]fluorodeoxyglucose in patients with chronic coronary artery disease. A functional and morphological approach to the detection of residual myocardial viability[J]. Circulation，1995，91（4）：1006-1015. DOI：10.1161/01.cir.91.4.1006.
[34]	GELEIJNSE M L，FIORETTI P M，ROELANDT J R. Methodology，feasibility，safety and diagnostic accuracy of dobutamine stress echocardiography[J]. J Am Coll Cardiol，1997，30（3）：595-606. DOI：10.1016/s0735-1097(97)00206-4.
[35]	ELHENDY A，CORNEL J H，ROELANDT J R，et al. Relation between contractile response of akinetic segments during dobutamine stress echocardiography and myocardial ischemia assessed by simultaneous thallium-201 single-photon emission computed tomography[J]. Am J Cardiol，1996，77（11）：955-959. DOI：10.1016/s0002-9149(96)00009-4.
[36]	AFRIDI I，QURESHI U，KOPELEN H A，et al. Serial changes in response of hibernating myocardium to inotropic stimulation after revascularization：a dobutamine echocardiographic study[J]. J Am Coll Cardiol，1997，30（5）：1233-1240. DOI：10.1016/s0735-1097(97)00308-2.
[37]	HAQUE T，FURUKAWA T，TAKAHASHI M，et al. Identification of hibernating myocardium by dobutamine stress echocardiography：comparison with thallium-201 reinjection imaging[J]. Am Heart J，1995，130（3 Pt 1）：553-563. DOI：10.1016/0002-8703(95)90366-6.
[38]	VANOVERSCHELDE J L，D'HONDT A M，MARWICK T，et al. Head-to-head comparison of exercise-redistribution-reinjection thallium single-photon emission computed tomography and low dose dobutamine echocardiography for prediction of reversibility of chronic left ventricular ischemic dysfunction[J]. J Am Coll Cardiol，1996，28（2）：432-442. DOI：10.1016/0735-1097(96)00167-2.
[39]	ABDUL GHAFFAR Y，MASKOUN W，MUSTAFA N G，et al. Low dose wall motion score predicts the short and long-term benefit of surgical revascularization in patients with ischemic left ventricular dysfunction[J]. Int J Cardiovasc Imaging，2019，35（9）：1651-1659. DOI：10.1007/s10554-019-01614-9.
[40]	ATABAEVA L S，SAIDOVA M A，SHITOV V N，et al. Comparison of myocardial contrast stress-echocardiography and standard stress-echocardiography in detecting myocardial ischemia in patients with different severity of coronary artery stenoses[J]. Ter Arkh，2020，92（4）：45-50. DOI：10.26442/00403660.2020.04.000506.
[41]	MOIR S，HALUSKA B A，JENKINS C，et al. Incremental benefit of myocardial contrast to combined dipyridamole-exercise stress echocardiography for the assessment of coronary artery disease[J]. Circulation，2004，110（9）：1108-1113. DOI：10.1161/01.CIR.0000139905.47128.9F.
[42]	LI D Y，HAO J，XIA Y，et al. Clinical usefulness of low-dose dobutamine stress real-time myocardial contrast echocardiography for detection of viable myocardium[J]. J Clin Ultrasound，2012，40（5）：272-279. DOI：10.1002/jcu.20891.
[43]	VOIGT J U，CVIJIC M. 2- and 3-dimensional myocardial strain in cardiac health and disease[J]. JACC Cardiovasc Imaging，2019，12（9）：1849-1863. DOI：10.1016/j.jcmg.2019.01.044.
[44]	WANG C F，HAN S G，XU T D，et al. Evaluation of myocardial viability in old myocardial infarcted patients with CHF：delayed enhancement MRI vs. low-dose dobutamine stress speckle tracking echocardiography[J]. Am J Transl Res，2016，8（9）：3731-3743.
[45]	GONG L，LI D Y，CHEN J H，et al. Assessment of myocardial viability in patients with acute myocardial infarction by two-dimensional speckle tracking echocardiography combined with low-dose dobutamine stress echocardiography[J]. Int J Cardiovasc Imaging，2013，29（5）：1017-1028. DOI：10.1007/s10554-013-0185-y.
[46]	SHARMA A，SOOD A，MITTAL B R，et al. Assessment of myocardial viability using echocardiographic strain imaging in patients with ST-elevation myocardial infarction：comparison with cardiac PET imaging[J]. J Echocardiogr，2020，18（4）：240-252. DOI：10.1007/s12574-020-00476-8.
[47]	LING L F，MARWICK T H，FLORES D R，et al. Identification of therapeutic benefit from revascularization in patients with left ventricular systolic dysfunction：inducible ischemia versus hibernating myocardium[J]. Circ Cardiovasc Imaging，2013，6（3）：363-372. DOI：10.1161/CIRCIMAGING.112.000138.
[48]	PANZA J A，ELLIS A M，AL-KHALIDI H R，et al. Myocardial viability and long-term outcomes in ischemic cardiomyopathy[J]. N Engl J Med，2019，381（8）：739-748. DOI：10.1056/NEJMoa1807365.
[49]	BEANLANDS R S B，NICHOL G，HUSZTI E，et al. F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease：a randomized，controlled trial （PARR-2）[J]. J Am Coll Cardiol，2007，50（20）：2002-2012. DOI：10.1016/j.jacc.2007.09.006.
[50]	ARDLE B M，SHUKLA T，NICHOL G，et al. Long-term follow-up of outcomes with F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction secondary to coronary disease[J]. Circ Cardiovasc Imaging，2016，9（9）：e004331. DOI：10.1161/CIRCIMAGING.115.004331.
[51]	CLELAND J G，CALVERT M，FREEMANTLE N，et al. The heart failure revascularisation trial（HEART）[J]. Eur J Heart Fail，2011，13（2）：227-233. DOI：10.1093/eurjhf/hfq230.
[52]	PERERA D，RYAN M，MORGAN H P，et al. Viability and outcomes with revascularization or medical therapy in ischemic ventricular dysfunction：a prespecified secondary analysis of the REVIVED-BCIS2 trial[J]. JAMA Cardiol，2023，8（12）：1154-1161. DOI：10.1001/jamacardio.2023.3803.
[53]	CLELAND J G，PENNELL D J，RAY S G，et al. Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure （CHRISTMAS trial）：randomised controlled trial[J]. Lancet，2003，362（9377）：14-21. DOI：10.1016/s0140-6736(03)13801-9.
[54]	YPENBURG C，SCHALIJ M J，BLEEKER G B，et al. Impact of viability and scar tissue on response to cardiac resynchronization therapy in ischaemic heart failure patients[J]. Eur Heart J，2007，28（1）：33-41. DOI：10.1093/eurheartj/ehl379.